Jazz Pharmaceuticals Statistics
Share Statistics
Jazz Pharmaceuticals has 60.45M shares outstanding. The number of shares has increased by -1.91% in one year.
| Shares Outstanding | 60.45M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | -2.08% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 57.91M |
| Failed to Deliver (FTD) Shares | 299 |
| FTD / Avg. Volume | 0.05% |
Short Selling Information
The latest short interest is 3.59M, so 5.94% of the outstanding shares have been sold short.
| Short Interest | 3.59M |
| Short % of Shares Out | 5.94% |
| Short % of Float | 6.17% |
| Short Ratio (days to cover) | 7.01 |
Valuation Ratios
The PE ratio is 18.77 and the forward PE ratio is 5.92. Jazz Pharmaceuticals's PEG ratio is 0.16.
| PE Ratio | 18.77 |
| Forward PE | 5.92 |
| PS Ratio | 2.03 |
| Forward PS | 1.7 |
| PB Ratio | 2.08 |
| P/FCF Ratio | 7.29 |
| PEG Ratio | 0.16 |
Enterprise Valuation
Jazz Pharmaceuticals has an Enterprise Value (EV) of 13.58B.
| EV / Earnings | 32.74 |
| EV / Sales | 3.54 |
| EV / EBITDA | 10.55 |
| EV / EBIT | 23.47 |
| EV / FCF | 12.72 |
Financial Position
The company has a current ratio of 2.24, with a Debt / Equity ratio of 1.53.
| Current Ratio | 2.24 |
| Quick Ratio | 1.85 |
| Debt / Equity | 1.53 |
| Total Debt / Capitalization | 60.45 |
| Cash Flow / Debt | 0.19 |
| Interest Coverage | 2 |
Financial Efficiency
Return on equity (ROE) is 0.11% and return on capital (ROIC) is 8.52%.
| Return on Equity (ROE) | 0.11% |
| Return on Assets (ROA) | 0.04% |
| Return on Capital (ROIC) | 8.52% |
| Revenue Per Employee | 1.37M |
| Profits Per Employee | 148.15K |
| Employee Count | 2.80K |
| Asset Turnover | 0.34 |
| Inventory Turnover | 0.73 |
Taxes
| Income Tax | -119.91M |
| Effective Tax Rate | -0.4 |
Stock Price Statistics
The stock price has increased by 1.23% in the last 52 weeks. The beta is 0.57, so Jazz Pharmaceuticals's price volatility has been higher than the market average.
| Beta | 0.57 |
| 52-Week Price Change | 1.23% |
| 50-Day Moving Average | 116.83 |
| 200-Day Moving Average | 112.56 |
| Relative Strength Index (RSI) | 57.5 |
| Average Volume (20 Days) | 610.20K |
Income Statement
In the last 12 months, Jazz Pharmaceuticals had revenue of $3.83B and earned $414.83M in profits. Earnings per share was $6.95.
| Revenue | 3.83B |
| Gross Profit | 3.40B |
| Operating Income | 578.58M |
| Net Income | 414.83M |
| EBITDA | 1.29B |
| EBIT | 578.58M |
| Earnings Per Share (EPS) | 6.95 |
Balance Sheet
The company has $1.51B in cash and $5.79B in debt, giving a net cash position of -$4.29B.
| Cash & Cash Equivalents | 1.51B |
| Total Debt | 5.79B |
| Net Cash | -4.29B |
| Retained Earnings | 878.66M |
| Total Assets | 12.26B |
| Working Capital | 3.36B |
Cash Flow
In the last 12 months, operating cash flow was $1.09B and capital expenditures -$23.96M, giving a free cash flow of $1.07B.
| Operating Cash Flow | 1.09B |
| Capital Expenditures | -23.96M |
| Free Cash Flow | 1.07B |
| FCF Per Share | 16.88 |
Margins
Gross margin is 88.64%, with operating and profit margins of 15.09% and 10.82%.
| Gross Margin | 88.64% |
| Operating Margin | 15.09% |
| Pretax Margin | 7.77% |
| Profit Margin | 10.82% |
| EBITDA Margin | 33.59% |
| EBIT Margin | 15.09% |
| FCF Margin | 27.86% |
Dividends & Yields
JAZZ does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | 5.65% |
| FCF Yield | 14.36% |
Analyst Forecast
The average price target for JAZZ is $174, which is 41.5% higher than the current price. The consensus rating is "Buy".
| Price Target | $174 |
| Price Target Difference | 41.5% |
| Analyst Consensus | Buy |
| Analyst Count | 14 |
Scores
| Altman Z-Score | 1.54 |
| Piotroski F-Score | 7 |